- Home
- SABS vs EVAX Comparison
SABS vs EVAX Comparison
Compare SABS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- EVAX
- Stock Information
- Founded
- SABS 2014
- EVAX 2008
- Country
- SABS United States
- EVAX Denmark
- Employees
- SABS N/A
- EVAX N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SABS Health Care
- EVAX Health Care
- Exchange
- SABS Nasdaq
- EVAX Nasdaq
- Market Cap
- SABS 19.0M
- EVAX 16.3M
- IPO Year
- SABS N/A
- EVAX 2021
- Fundamental
- Price
- SABS $1.82
- EVAX $2.53
- Analyst Decision
- SABS Strong Buy
- EVAX Strong Buy
- Analyst Count
- SABS 5
- EVAX 3
- Target Price
- SABS $12.40
- EVAX $33.33
- AVG Volume (30 Days)
- SABS 246.2K
- EVAX 6.8M
- Earning Date
- SABS 03-28-2025
- EVAX 03-26-2025
- Dividend Yield
- SABS N/A
- EVAX N/A
- EPS Growth
- SABS N/A
- EVAX N/A
- EPS
- SABS N/A
- EVAX N/A
- Revenue
- SABS $1,512,723.00
- EVAX $3,295,000.00
- Revenue This Year
- SABS N/A
- EVAX $9,039.73
- Revenue Next Year
- SABS N/A
- EVAX $1.47
- P/E Ratio
- SABS N/A
- EVAX N/A
- Revenue Growth
- SABS N/A
- EVAX N/A
- 52 Week Low
- SABS $1.60
- EVAX $2.22
- 52 Week High
- SABS $6.30
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- SABS 36.28
- EVAX 40.91
- Support Level
- SABS $2.00
- EVAX $2.43
- Resistance Level
- SABS $2.15
- EVAX $2.80
- Average True Range (ATR)
- SABS 0.20
- EVAX 0.31
- MACD
- SABS 0.03
- EVAX 0.07
- Stochastic Oscillator
- SABS 30.99
- EVAX 16.94
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.